#pancreatic cancer #Akeso #Cadonilimab

Significant Advances in Pancreatic Cancer Treatment with Cadonilimab

In a significant advancement for the treatment of locally advanced pancreatic cancer, Akeso, Inc. recently presented promising Phase II results obtained from the COMPASSION-26 study at the American Association for Cancer Research (AACR) Annual Meeting in 2026. The study evaluates the efficacy of cadonilimab, a groundbreaking first-in-class bispecific antibody designed to target both PD-1 and CTLA-4 in combination with standard chemotherapy as a first-line treatment.

Compelling Data Highlights

The Phase II data showcases impressive outcomes for patients suffering from pancreatic ductal adenocarcinoma (PDAC), particularly emphasizing its benefits for those with locally advanced disease. As of October 20, 2025, the combination of cadonilimab and chemotherapy demonstrated robust survival metrics during a follow-up period exceeding two years.

Notably, the median progression-free survival (PFS) was recorded at 11.1 months, while the median overall survival (OS) surpassed a significant 23 months among the studied patients. More strikingly, the data illustrates a remarkable 12-month OS rate of 91.7% and a 24-month OS rate of 44.1%. These statistics underscore the potential of cadonilimab to provide enduring therapeutic benefits to this challenging patient population.

For those evaluable for efficacy, with 95% undergoing at least one tumor assessment post-baseline, the objective response rate (ORR) reached 33.9%. Furthermore, a disease control rate (DCR) of 96.4% was achieved, reflecting the treatment's overall effectiveness.

Importantly, response rates were uniform between patients diagnosed with locally advanced disease and those with metastatic disease, signifying that the treatment’s benefits span various disease manifestations.

Safety Profile and Future Implications

The safety profile of the cadonilimab combination remains favorable, with no new safety signals identified during the study period. This aspect is vital, as it reassures both patients and healthcare providers regarding the manageability of potential side effects associated with this innovative treatment.

Cadonilimab holds the distinction as the world’s first approved bispecific antibody for the realm of cancer immunotherapy, receiving marketing approval back in 2022. The ongoing clinical development and robust real-world application of cadonilimab demonstrate its ability to meet significant unmet clinical needs, generating considerable acclaim from physicians and patients alike. It effectively addresses a noteworthy gap, particularly among those exhibiting diverse PD-L1 expression statuses.

A Transformative Era in Cancer Treatment

Widely recognized as a cornerstone therapy in the progressing landscape of tumor immunotherapy 2.0, cadonilimab not only provides substantial clinical advantages across varied patient demographics but also exhibits breakthrough potential in treating particularly challenging cases, such as immunotherapy-refractory diseases and those associated with